Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma

Sorafenib (Nexavar), a multiple kinase inhibitor, is the only clinically approved drug for patients with advanced HCC. However, its therapeutic success is limited by the emergence of drug resistance. Here we found that p21 and pGSK3β(Ser9) are major players in the resistance to sorafenib. We recentl...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Giovannini, Catia, Baglioni, Michele, Toaldo, Marco Baron, Ventrucci, Cristiano, D'Adamo, Stefania, Cipone, Mario, Chieco, Pasquale, Gramantieri, Laura, Bolondi, Luigi
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Impact Journals LLC 2013
Θέματα:
Research Paper
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3858550/
https://ncbi.nlm.nih.gov/pubmed/24113128
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια